Literature DB >> 8245546

Low serum levels of oral antimycobacterial agents in patients with disseminated Mycobacterium avium complex disease.

S M Gordon1, C R Horsburgh, C A Peloquin, J A Havlik, B Metchock, L Heifets, J E McGowan, S E Thompson.   

Abstract

Twenty-seven human immunodeficiency virus-infected patients with disseminated Mycobacterium avium complex disease who were treated with oral antimycobacterial agents (clofazimine, ciprofloxacin, ethambutol, and rifampin) were studied to evaluate the usefulness of monitoring serum drug concentrations and testing in vitro susceptibility of M. avium complex (MAC) isolates. Twenty patients tolerated treatment with three or four antimycobacterial agents for at least 8 weeks; mycobacteremia was eradicated in 7 (35%). The in vitro susceptibilities of MAC isolates to antimycobacterial agents were similar for these 7 and for the 13 who did not respond to antimycobacterial treatment. Serum drug levels were below the expected range in 6 of the 7 whose mycobacteremia was cleared and in 9 of the 13 nonresponders (P = .41). These low serum concentrations of antimycobacterial drugs may be due to impaired drug absorption in patients with AIDS and disseminated MAC disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8245546     DOI: 10.1093/infdis/168.6.1559

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  19 in total

1.  Pharmacokinetics of rifabutin in HIV-infected patients with or without wasting syndrome.

Authors:  G Gatti; A Di Biagio; C R De Pascalis; M Guerra; M Bassetti; D Bassetti
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

Review 2.  Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.

Authors:  W J Burman; K Gallicano; C Peloquin
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 3.  Susceptibility testing of Mycobacterium avium complex isolates.

Authors:  L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

Review 4.  Therapeutic drug monitoring in the treatment of tuberculosis: an update.

Authors:  Abdullah Alsultan; Charles A Peloquin
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

5.  Effects of AIDS and gender on steady-state plasma and intrapulmonary ethionamide concentrations.

Authors:  J E Conte; J A Golden; M McQuitty; J Kipps; E T Lin; E Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

6.  Effect of sex and AIDS status on the plasma and intrapulmonary pharmacokinetics of rifampicin.

Authors:  John E Conte; Jeffrey A Golden; Juliana E Kipps; Emil T Lin; Elisabeth Zurlinden
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

7.  Effects of gender, AIDS, and acetylator status on intrapulmonary concentrations of isoniazid.

Authors:  John E Conte; Jeffrey A Golden; Mari McQuitty; Juliana Kipps; Sheila Duncan; Elaine McKenna; Elisabeth Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

8.  Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.

Authors:  Luis F López-Cortés; Rosa Ruiz-Valderas; Pompeyo Viciana; Aristides Alarcón-González; Jesús Gómez-Mateos; Eva León-Jimenez; Maria Sarasanacenta; Yolanda López-Pua; Jerónimo Pachón
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 9.  Mycobacterium avium complex: advances in therapy.

Authors:  D V Havlir
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-11       Impact factor: 3.267

10.  Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients.

Authors:  G Gatti; P Papa; D Torre; M Andreoni; A Poggio; M Bassetti; P Marone
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.